John Libbey Eurotext

Generic substitutions of antiseizure medications: recommendations issued by the Israeli Chapter of the International League Against Epilepsy Article à paraître

Tableaux

Auteurs
1 Epilepsy and EEG Unit, Neurology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 Pediatric Epilepsy and Neurology Service, Barzilai Medical Center, Ashkelon, Israel
4 Department of Neurology, Rambam Health Care Center, Haifa, Israel
5 Faculty of Medicine, Technion, Institute of Technology, Haifa, Israel
6 Pediatric Neurology Unit, Soroka University Medical Center, Israel
7 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
8 Department of Neurology, Agnes Ginges Center of Human Neurogenetics, Hadassah Medical Organization, Jerusalem, Israel
9 Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
10 Pediatric Neurology Unit, Safra Pediatric Hospital, Sheba Medical Center, Tel Hashomer, Israel
11 Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
Correspondence:
Sara Eyal
Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Ein Kerem, Jerusalem, 91120, Israel

To the Editor,While generic drug formulations have been advocated by regulators [1], specific concerns have arisen regarding their use in the treatment of epilepsy. This is because:many bioequivalence studies have relied only on healthy volunteers and do not reflect the variability among patients with epilepsy;focusing on the average could have missed patients who are particularly sensitive to generic switches;and the acceptable bioequivalence range of 80%–125% (the 90% confidence interval for the [...]